Follow-on drugs: Circumventing the customary patent cliffs in Big Pharma

October 30, 2018

Follow-on drugs, also referred to as ‘next-generation drugs’, are ‘an established practice’ among drug innovators. They are one of the most effective R&D strategies implemented by drug innovators, and can be considered a cannibalization or switching strategy. In a nutshell, it is a timely switch from a mature/firstgeneration drug to its next-generation, improved version. Given the fixed patent term and limited market exclusivity of drugs, cannibalization has been instrumental in maintaining the market share for drug makers.

Spotlight

AL ANDALOUS PHARMACEUTICAL SERVICES ( APS )

Al Andalous Pharmaceutical Services (APS) a privately owned Egyptian company, established in 2006 with a two-fold mission: - Partner with international innovative pharmaceutical and medical device companies to bring innovative specialty products to Egypt and ME region - Provide world-class services and consulting to pharmaceutical industry - focus on regulatory , government affairs and clinical research services APS combines local expertise and access with a multinational perspective, building on the existing leadership and strong position of sister company Al Andalous Medical Company in the Egyptian market.

OTHER WHITEPAPERS
news image

Prescription Drug Pricing: How Lack of Transparency Reduces Market Access, Utilization, and Adherence

whitePaper | November 25, 2019

It's clear that healthcare prices weigh heavily on the minds of Americans, and the time has come for the pharmaceutical industry to take the reins of the prescription drug pricing dialogue with consumers.

Read More
news image

Assessing drug target association from biological evidences

whitePaper | July 7, 2022

The full drug target profile identification is many times a necessary step in drug development process. Recently, the move to a more holistic approach in drug discovery has resulted in the increasing use of cell-based assays to discover new biologically active small molecules.

Read More
news image

A Brief Synopsis of Modern Randomization Methodologies and Technologies

whitePaper | December 9, 2022

Randomized, double-blind clinical trials are the gold standard for adequate and well-controlled studies in modern times. However, prior to the late 1940s, randomization and blinding were not used in medicine and as result, bias was common.

Read More
news image

Benefits of Semantic Enrichment Across the Drug Development Pipeline

whitePaper | January 24, 2022

Semantics is the process of assigning meaning to words and is a vital step in making unstructured scientific content machine readable, contextualizing otherwise unstructured information. It unlocks a host of benefits to search and analytics which are outlined below in the context of use cases relevant to drug discovery.

Read More
news image

Understanding Net Pharmaceutical Expenditure Dynamics in Europe

whitePaper | April 12, 2022

The level of pharmaceutical expenditure is closely watched and often commented upon, but the composition of that expenditure and its dynamics are not as well understood.

Read More
news image

Measuring the COVID Effect on Clinical Trials

whitePaper | June 27, 2022

As the world begins its transition into a postpandemic existence, it becomes possible to look back on the past two years and begin to quantify the effects that COVID-19 has brought.

Read More

Spotlight

AL ANDALOUS PHARMACEUTICAL SERVICES ( APS )

Al Andalous Pharmaceutical Services (APS) a privately owned Egyptian company, established in 2006 with a two-fold mission: - Partner with international innovative pharmaceutical and medical device companies to bring innovative specialty products to Egypt and ME region - Provide world-class services and consulting to pharmaceutical industry - focus on regulatory , government affairs and clinical research services APS combines local expertise and access with a multinational perspective, building on the existing leadership and strong position of sister company Al Andalous Medical Company in the Egyptian market.

Events